Hui Gan

14.8k total citations · 3 hit papers
326 papers, 7.5k citations indexed

About

Hui Gan is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Hui Gan has authored 326 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 80 papers in Genetics and 70 papers in Molecular Biology. Recurrent topics in Hui Gan's work include Glioma Diagnosis and Treatment (78 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Hui Gan is often cited by papers focused on Glioma Diagnosis and Treatment (78 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Hui Gan collaborates with scholars based in Australia, China and United States. Hui Gan's co-authors include Andrew M. Scott, Sagun Parakh, Terrance G. Johns, Umbreen Hafeez, Rodney B. Luwor, Benoît You, Anna N. Cvrljevic, Andrew H. Kaye, Julien Péron and Taolei Sun and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Hui Gan

305 papers receiving 7.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk factors for severe and critically ill COVID‐19 patients: A review

2020 850 citations Hui Gan et al. profile →
Antibody–Drug Conjugates for Cancer Therapy

2020 278 citations Sagun Parakh, Hui Gan et al. Molecules profile →
Pharmacological Effects of Astragaloside IV: A Review

2023 87 citations Zhiyun Meng, Hui Gan et al. Molecules profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Hui Gan	2.4k	1.9k	1.2k	1.2k	1.2k	326	7.5k
Lynette M. Smith	2.9k 1.2×	2.1k 1.1×	880 0.7×	464 0.4×	1.3k 1.1×	299	8.8k
Eugene P. Frenkel	2.6k 1.1×	3.1k 1.7×	948 0.8×	670 0.6×	1.4k 1.2×	203	9.5k
Sang‐Cheol Bae	1.6k 0.6×	2.1k 1.1×	1.3k 1.0×	1.8k 1.5×	703 0.6×	501	16.5k
William L. Carroll	2.8k 1.1×	2.8k 1.5×	1.1k 0.9×	487 0.4×	707 0.6×	316	13.6k
Keith R. McCrae	1.1k 0.4×	2.6k 1.4×	1.6k 1.3×	381 0.3×	966 0.8×	252	10.8k
Gertjan J.L. Kaspers	4.0k 1.6×	6.6k 3.5×	2.0k 1.6×	435 0.4×	1.2k 1.1×	538	18.4k
Kihyun Kım	3.3k 1.4×	2.3k 1.2×	808 0.6×	189 0.2×	904 0.8×	403	8.1k
Ömer Yılmaz	2.3k 0.9×	4.5k 2.4×	944 0.8×	1.8k 1.5×	818 0.7×	456	13.5k
Feng Gao	4.8k 2.0×	2.9k 1.5×	651 0.5×	1.3k 1.1×	3.0k 2.6×	473	13.4k
Anna K. Nowak	4.2k 1.7×	1.6k 0.8×	931 0.7×	952 0.8×	5.1k 4.5×	358	11.3k

Countries citing papers authored by Hui Gan

Since Specialization

Citations

This map shows the geographic impact of Hui Gan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Gan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Gan more than expected).

Fields of papers citing papers by Hui Gan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Gan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Gan. The network helps show where Hui Gan may publish in the future.

Co-authorship network of co-authors of Hui Gan

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Gan. A scholar is included among the top collaborators of Hui Gan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Gan. Hui Gan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tao, Yuan, Miaomiao Yao, Xi Kang, et al.. (2025). Xanthoceras sorbifolium Oil Attenuates Hyperlipidemia Through Dual Modulation of Gut Microbiota and Lipid Metabolites: Mechanistic Insights from Lipidomics and 16S rRNA Sequencing. Metabolites. 15(5). 291–291.

Parakh, Sagun, Deliang Cao, Angela Rigopoulos, et al.. (2025). Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2. 1 indexed citations

Chauhan, Ashfaq, Melvin Chin, Meron Pitcher, et al.. (2025). Patient Safety Events Among People from Ethnic Minority Backgrounds: A Retrospective Medical Record Review of Australian Cancer Services. Journal of Racial and Ethnic Health Disparities. 13(2). 1094–1105. 1 indexed citations

Zhang, Qin, et al.. (2024). Long Noncoding RNA GAS5-Involved Progression of Neonatal Hydrocephalus and Inflammatory Responses. Molecular Biotechnology. 67(2). 661–672. 1 indexed citations

Ng, Sweet Ping, Richard Khor, Morikatsu Wada, et al.. (2024). Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours. Journal of Clinical Medicine. 13(11). 3020–3020. 2 indexed citations

Han, Xiao, et al.. (2023). Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data. Translational Pediatrics. 12(4). 681–694. 3 indexed citations

Wang, Wanmei, et al.. (2023). Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury. Molecules. 28(11). 4441–4441. 5 indexed citations

Rotow, Julia, Saiama N. Waqar, K. Papadopoulos, et al.. (2023). 1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S759–S759. 4 indexed citations

Mair, Maximilian J., Rupert Bartsch, Émilie Le Rhun, et al.. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology. 20(6). 372–389. 45 indexed citations

10.

Huynh, Nhi, Angela Rigopoulos, Zhanqi Liu, et al.. (2023). Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography. Chemical Communications. 59(21). 3126–3129. 1 indexed citations

11.

Gao, Ya, Yulu Liu, Zhuona Wu, et al.. (2022). Evaluation of the metabolism of PEP06, an endostatin-RGDRGD 30-amino-acid polypeptide and a promising novel drug for targeting tumor cells. Journal of Pharmaceutical Analysis. 12(5). 766–773. 2 indexed citations

12.

Meng, Zhiyun, Xiaoxia Zhu, Zhuona Wu, et al.. (2022). A rapid quantitative method by liquid chromatography–tandem mass spectrometry for the measurement of anthocyanins and their metabolic characteristics in Sprague–Dawley rats. European Food Research and Technology. 248(8). 2109–2124. 3 indexed citations

13.

Nguyen, Hong, Vijay Rajagopal, Magdalene K. Montgomery, et al.. (2021). EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism. Cancers. 13(6). 1198–1198. 12 indexed citations

14.

Anderson, Mark G., Hugh D. Falls, Michael J. Mitten, et al.. (2020). Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate. Molecular Cancer Therapeutics. 19(10). 2117–2125. 30 indexed citations

15.

Leimgruber, Antoine, Kevin Hickson, Sze Ting Lee, et al.. (2020). Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. European Journal of Nuclear Medicine and Molecular Imaging. 47(6). 1476–1485. 19 indexed citations

16.

Muralidharan, Vijayaragavan, Niall C. Tebbutt, Pok Fai Wong, et al.. (2020). Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 48(5). 1585–1592. 4 indexed citations

17.

Gan, Hui, Michael Millward, Hua Ye, et al.. (2019). First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity. Clinical Cancer Research. 25(16). 4924–4932. 41 indexed citations

18.

Lassman, Andrew B., Lisa Roberts-Rapp, И. А. Соколова, et al.. (2019). Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research. 25(11). 3259–3265. 25 indexed citations

19.

Tully, Patrick, Elizabeth H Barnes, Zarnie Lwin, et al.. (2018). Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study. Journal of Neuro-Oncology. 137(2). 409–415. 51 indexed citations

20.

Péron, Julien, Denis Maillet, Hui Gan, Eric X. Chen, & Benoît You. (2013). Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. Journal of Clinical Oncology. 31(31). 3957–3963. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact